Passage Bio, Inc. cash flow to debt ratio of -131.23% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Passage Bio, Inc.'s free cash flow has increased -34.34% from $-47.99M last year to $-31.51M, signaling increasing performance

Passage Bio, Inc.'s debt to equity ratio is 0.49, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Passage Bio, Inc.'s debt has increased relative to shareholder equity from 0.42 last year to 0.49 today, signaling weakened financials

Passage Bio, Inc. has negative EBITDA, making leverage ratio unreliable

Passage Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Passage Bio, Inc. has insufficient data to evaluate this check.

Passage Bio, Inc.'s short-term assets of $47.76M exceed its short-term liabilities of $23.08M

Passage Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Passage Bio, Inc.'s return on equity of -150.88%, is lower than 15.00%, indicating bad performance

Passage Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Passage Bio, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Passage Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Passage Bio, Inc. has negative free cash flow, indicating cash burn

Passage Bio, Inc.'s yearly earnings has increased -29.71% since last year from $-64.77M to $-45.52M, signaling increasing performance

Passage Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -238.29% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Passage Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Passage Bio, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Passage Bio, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Passage Bio, Inc. has insufficient data to evaluate this check.

Passage Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Passage Bio, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Passage Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Passage Bio, Inc. has insufficient data to evaluate this check.

Passage Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Passage Bio, Inc. has a price-to-book ratio of 1.21x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Passage Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue